Literature DB >> 15965712

CD4 T cells in tumor immunity.

Mara Gerloni1, Maurizio Zanetti.   

Abstract

T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965712     DOI: 10.1007/s00281-004-0193-z

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  82 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Role of CD8+ T cells in murine experimental allergic encephalomyelitis.

Authors:  H Jiang; S I Zhang; B Pernis
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

3.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.

Authors:  L Fransen; J Van der Heyden; R Ruysschaert; W Fiers
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

4.  Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

Authors:  K O Lloyd; J Burchell; V Kudryashov; B W Yin; J Taylor-Papadimitriou
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

5.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

Authors:  R F Wang; X Wang; A C Atwood; S L Topalian; S A Rosenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

6.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

8.  Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Authors:  Cristina Maccalli; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  30 in total

1.  Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.

Authors:  Emmanuel S Antonarakis; Eric J Small; Daniel P Petrylak; David I Quinn; Adam S Kibel; Nancy N Chang; Erica Dearstyne; Matt Harmon; Dwayne Campogan; Heather Haynes; Tuyen Vu; Nadeem A Sheikh; Charles G Drake
Journal:  Clin Cancer Res       Date:  2018-06-01       Impact factor: 12.531

2.  High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.

Authors:  Andrew G Brandmaier; Wolfgang W Leitner; Sung P Ha; John Sidney; Nicholas P Restifo; Christopher E Touloukian
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

3.  Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma.

Authors:  Lixia Zhang; Jinyan Chen; Caiyun Xu; Lili Qi; Yan Ren
Journal:  Exp Ther Med       Date:  2017-12-21       Impact factor: 2.447

4.  Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.

Authors:  Olivia I Koues; R Kyle Dudley; Agnieszka D Truax; Dawson Gerhardt; Kavita P Bhat; Sam McNeal; Susanna F Greer
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

5.  Th9 cells promote antitumor immune responses in vivo.

Authors:  Yong Lu; Sungyoul Hong; Haiyan Li; Jungsun Park; Bangxing Hong; Lijuan Wang; Yuhuan Zheng; Zhiqiang Liu; Jingda Xu; Jin He; Jing Yang; Jianfei Qian; Qing Yi
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

6.  Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.

Authors:  I Heier; P O Hofgaard; P Brandtzaeg; F L Jahnsen; M Karlsson
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

7.  Roles for common MLL/COMPASS subunits and the 19S proteasome in regulating CIITA pIV and MHC class II gene expression and promoter methylation.

Authors:  Olivia I Koues; Ninad T Mehta; Agnieszka D Truax; R Kyle Dudley; Jeanne K Brooks; Susanna F Greer
Journal:  Epigenetics Chromatin       Date:  2010-02-04       Impact factor: 4.954

8.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

9.  T cell survival and function requires the c-Abl tyrosine kinase.

Authors:  Isabelle Silberman; Ronit Vogt Sionov; Valentina Zuckerman; Sue Haupt; Zehavit Goldberg; Andreas Strasser; Zami S Ben-Sasson; Michal Baniyash; Anthony J Koleske; Ygal Haupt
Journal:  Cell Cycle       Date:  2008-12-23       Impact factor: 4.534

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.